Skip to main content

Table 3 Gender related difference in nadir blood counts after C1 and C3

From: Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review

 

Gender

Mean difference

95% CI

P-value

Male

Female

N

Mean

SD

N

Mean

SD

Neutrophil nadir

         

  VDC

         

  Cycle 1

13

1.56

1.35

9

0.16

0.19

1.40

(0.57, 2.21)

0.003

  Cycle 3

12

1.59

1.08

9

0.42

0.56

1.17

(0.40, 1.93)

0.005

  IE

         

  Cycle 2

13

3.77

2.70

10

4.40

4.59

−0.63

(−4.14, 2.88)

0.71

  Cycle 4

12

3.17

3.54

9

0.86

1.18

2.31

(−0.04, 4.66)

0.05

Dose intensity (%)

         

  VDC

13

107

9

10

98

16

9

(−3, 22)

0.12

  IE

13

105

7

10

102

11

3

(−5, 11)

0.49

  1. P–values correspond to comparisons between genders. Dose intensity of VDC and IE is compared to baseline.
Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329